Tyrosine Kinase Inhibitors CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy EGFR BCL Inhibitors Chemotherapy PARP Inhibitors IGF Cyclin Dependent Kinase Inhibitors Serine-Threonine Kinase Inhibitors | HER2 Positive Breast Cancer | HER2 Negative Breast Cancer |
---|---|---|
trastuzumab + pertuzumab | ||
trastuzumab + lapatinib | ||
QL1209 (pertuzumab biosimilar) | ||
carboplatin + paclitaxel | ||
olaparib | ||
tegafur/uracil | ||
pertuzumab | ||
AMG 479 | ||
pertuzumab + ado-trastuzumab emtansine | ||
lapatinib | ||
pembrolizumab | ||
trastuzumab | ||
paclitaxel + doxorubicin hydrochloride | ||
ado-trastuzumab emtansine | ||
margetuximab | ||
bevacizumab + disitamab vedotin | ||
pembrolizumab + pertuzumab + trastuzumab-qyyp | ||
trastuzumab + pyrotinib | ||
durvalumab + fam-trastuzumab deruxtecan-nxki | ||
cemiplimab-rwlc | ||
trastuzumab + TQB2303 (rituximab biosimilar) | ||
RVU120 | ||
TCHP | ||
CDK19 inhibitor | ||
CDK8 inhibitor |